Related Experiment Videos

Somatostatin suppresses growth of murine myeloid leukemia in vivo

Blood
|April 1, 1981
PubMed

Insights

Daily somatostatin injections slowed myeloid leukemia growth in mice. This effect is linked to somatostatin reducing insulin levels, which are crucial for this insulin-dependent tumor

Area of Science:

  • Endocrinology and Oncology
  • Tumor Biology

Background:

  • Myeloid leukemia exhibits insulin dependency, growing slower in hypoinsulinemic states.
  • Insulin plays a role in the proliferation of certain tumor types.

Purpose of the Study:

  • To investigate the effect of somatostatin on myeloid leukemia tumor growth.
  • To elucidate the role of insulin in somatostatin's antileukemic activity.

Main Methods:

  • Administration of daily somatostatin injections to mice with myeloid leukemia.
  • Monitoring tumor growth and insulin levels in treated and control mice.
  • Assessing the impact of exogenous insulin administration on somatostatin's effect.

Main Results:

  • Somatostatin injections significantly retarded myeloid leukemia tumor growth.
  • Somatostatin treatment led to decreased levels of immunoreactive insulin.
  • Exogenous insulin administration reversed the tumor growth retardation caused by somatostatin.

Conclusions:

  • Somatostatin exerts an antileukemic effect on myeloid leukemia by reducing insulin secretion.
  • Insulin is a key factor in the growth of this specific type of myeloid leukemia.
  • Targeting insulin secretion represents a potential therapeutic strategy for insulin-dependent myeloid leukemia.

Related Concept Videos